Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1574]

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in...

Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in mCRPC ( Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA )

Enfortumab vedotin in combination with pembrolizumab shows improved survival...

Prof Thomas Powles - Barts Cancer Institute, London, England

Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC ( Prof Thomas Powles - Barts Cancer Institute, London, England )

SIOG 2024: Updates in radiation oncology

Dr Lucinda Morris - Crown Princess Mary Cancer Centre, Westmead, Australia

SIOG 2024: Updates in radiation oncology ( Dr Lucinda Morris - Crown Princess Mary Cancer Centre, Westmead, Australia )

SIOG 2024: Updates in medical oncology

Dr Capucine Baldini - Gustave Roussy, Villejuif, France

SIOG 2024: Updates in medical oncology ( Dr Capucine Baldini - Gustave Roussy, Villejuif, France )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

Clinical and pathologic features of elderly breast cancer patients in Tunisia

Dr Houda Belfekih - Mohamed Taher Maamouri Hospital, Nabeul, Tunisia

Clinical and pathologic features of elderly breast cancer patients in Tunisia ( Dr Houda Belfekih - Mohamed Taher Maamouri Hospital, Nabeul, Tunisia )

Assessment and management of toxic effects of cancer therapy in elderly...

Dr Houda Belfekih - Mohamed Taher Maamouri Hospital, Nabeul, Tunisia

Assessment and management of toxic effects of cancer therapy in elderly patients in Tunisia ( Dr Houda Belfekih - Mohamed Taher Maamouri Hospital, Nabeul, Tunisia )

Everolimus plus lanreotide might be a new standard treatment in the first-line...

Dr Susumu Hijioka - National Cancer Center Hospital, Chuo City, Japan

Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs ( Dr Susumu Hijioka - National Cancer Center Hospital, Chuo City, Japan )

Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal...

Dr Efrat Dotan - University of Pennsylvania, Philadelphia, USA

Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal irinotecan shows similar results in older patients ( Dr Efrat Dotan - University of Pennsylvania, Philadelphia, USA )

Radiotherapy in Kharkiv

Dr Sergii Artiukh - National Academy of Sciences of Ukraine, Kyiv, Ukraine

Radiotherapy in Kharkiv ( Dr Sergii Artiukh - National Academy of Sciences of Ukraine, Kyiv, Ukraine )

Prostate cancer

Dr Alison Tree - Institute of Cancer Research, London, UK

Prostate cancer ( Dr Alison Tree - Institute of Cancer Research, London, UK )

Dr Sofia Rivera - Gustave Roussy, Villejuif, France

Breast cancer ( Dr Sofia Rivera - Gustave Roussy, Villejuif, France )

More from ecancer